Table 4:

Immunohistochemical findings in 14 eyes with retinoblastoma

Case No./Sex/Age (mo)	AES	VEGF		Flt-1		CD31
Case No./Sex/Age (mo)	Enhancement	Iris Surface	Iris Stroma	Iris Surface	Iris Stroma^a	IA^b
1/M/2	Normal	Strong	Weak	Weak	Weak	1
2/F/25	Normal	Weak	Negative	Negative	Negative	0
3/M/4	Normal	Strong	Weak	Weak	Weak	0
4/M/12	Normal	Negative	Negative	Negative	Negative	0
5/M/31	Normal	Strong	Weak	Negative	Weak	0
6/F/26	Moderate	Weak	Negative	Negative	Weak	0
7/F/16	Moderate	Strong	Weak	Strong	Weak	3
8/F/2	Moderate	Strong	Weak	Negative	Weak	0
9/M/2	Moderate	Strong	Strong	Negative	Weak	0
10/M/36	Strong	Weak	Negative	Negative	Weak	1
11/F/20	Strong	Negative	Negative	Negative	Weak	2
12/M/29	Strong	Weak	Negative	Negative	Weak	3
13/M/6	Strong	Strong	Weak	Strong	Strong	2
14/M/3	Strong	Strong	Weak	Negative	Weak	1

a Significant correlation between AES enhancement and the data in this column (r = .555; P = .04)
b Significant correlation between AES enhancement and the data in this column (r = .665; P = .009). IA according to the Pe'er classification.¹²